Alerts will be sent to your verified email
Verify Email
PDPL
|
Parenteral Drugs
|
Kabra Drugs
|
Kobo Biotech
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
23.74 % | 65.41 % | -1.77 % |
|
5yr average Equity Multiplier
|
-0.77 | -11.28 | 4.06 |
|
5yr Average Asset Turnover Ratio
|
0.06 | 0.0 | 0.54 |
|
5yr Avg Net Profit Margin
|
-606.74 % | 0.0 | -3.79 % |
|
Price to Book
|
0.0 | 7.92 | 0.0 |
|
P/E
|
0.0 | 0.0 | 0.0 |
|
5yr Avg Cash Conversion Cycle
|
-464.64 Days | 0.0 | 0.0 |
|
Inventory Days
|
77.96 Days | 0.0 | 89.28 Days |
|
Days Receivable
|
0.0 | 0.0 | 0.0 |
|
Days Payable
|
252.32 Days | 0.0 | 147.48 Days |
|
5yr Average Interest Coverage Ratio
|
0.75 | -836.53 | 0.99 |
|
5yr Avg ROCE
|
9.54 % | 64.57 % | 11.79 % |
|
5yr Avg Operating Profit Margin
|
-65.99 % | 0.0 | 8.83 % |
|
5 yr average Debt to Equity
|
-1.16 | -6.16 | 1.62 |
|
5yr CAGR Net Profit
|
-3.82 % | 65.28 % | n/a |
|
5yr Average Return on Assets
|
-30.49 % | -21.32 % | -0.89 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
73.29 % | 0.0 | 44.95 % |
|
Share Pledged by Promoters
|
94.5 % | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.01 % | 0.0 | 0.0 |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Parenteral Drugs
|
Kabra Drugs
|
Kobo Biotech
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|